Clinical trial · Observational
Strigolactones and Dysplastic Colonic Lesions or Cancer
The Effect of the Plant Hormones Strigolactones on Cultures of Dysplastic Colonic Lesions and Cancer
NCT02824835CI-TRIAL-00022927unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the effects of the plant hormones strigolactones, on cell cultures of colonic polyps and colorectal cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colonic Neoplasms | Colon Neoplasm | ALIAS | 0.90 |
| Colonic Polyps | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| biopsy during colonoscopy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- adenoma group
- description
- Patients with adenoma. Biopsies are taken before endoscopic resection.
- interventionNames
- Procedure: biopsy during colonoscopy
- label
- cancer group
- description
- Patients with colorectal cancer. Biopsies are taken before surgical resection.
- interventionNames
- Procedure: biopsy during colonoscopy
Primary outcomes (2)
- measure
- percentage of cells with reduced viability after dose-dependent exposure
- timeFrame
- 24 hours of exposure to strigolactone
- measure
- percentage of cells in G2/M arrest after dose-dependent exposure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with positive findings during colonoscopy Exclusion Criteria: * Patients below 18 years old * Patients who cannot sign a consent form
References
Publications (2)
- BACKGROUNDMayzlish-Gati E, Laufer D, Grivas CF, Shaknof J, Sananes A, Bier A, Ben-Harosh S, Belausov E, Johnson MD, Artuso E, Levi O, Genin O, Prandi C, Khalaila I, Pines M, Yarden RI, Kapulnik Y, Koltai H. Strigolactone analogs act as new anti-cancer agents in inhibition of breast cancer in xenograft model. Cancer Biol Ther. 2015;16(11):1682-8. doi: 10.1080/15384047.2015.1070982. Epub 2015 Jul 20. PMID 26192476
- BACKGROUNDPollock CB, Koltai H, Kapulnik Y, Prandi C, Yarden RI. Strigolactones: a novel class of phytohormones that inhibit the growth and survival of breast cancer cells and breast cancer stem-like enriched mammosphere cells. Breast Cancer Res Treat. 2012 Aug;134(3):1041-55. doi: 10.1007/s10549-012-1992-x. Epub 2012 Mar 29. PMID 22476848